Keyphrases
Cellular Effectors
12%
Clinical Trials
9%
Direct Evaluation
9%
Further Development
9%
Highly Active Antiretroviral Therapy (HAART)
18%
HIV Immunity
9%
HIV Infection
9%
HIV Status
9%
HIV Vaccine
75%
HIV-1 Recombinants
12%
Host Immunity
37%
Human Infection
9%
Human Peripheral Blood Lymphocytes
12%
Immune Function
9%
In Vivo Model
18%
Lentivirus
9%
Mouse Model
37%
Non-HIV
12%
Non-viral Vectors
9%
Pathogenic Mechanism
9%
Primary Immune Response
12%
Protective Immunity
28%
Recombinant Protein
9%
Scid
87%
Secondary Immune Response
12%
Specific Intent
9%
Vaccination
9%
Vaccine Construct
37%
Vaccine-induced Immunity
25%
Viral
9%
Viral Disease
9%
Viral Pathogenesis
9%
Viral Vaccines
12%
Immunology and Microbiology
HIV Vaccine
60%
Human Immunodeficiency Virus
60%
Human Immunodeficiency Virus 1
75%
Human Immunodeficiency Virus Infection
15%
Lentivirus
15%
Mouse
15%
Mouse Model
60%
Peripheral Blood Lymphocyte
100%
Primary Immune Response
20%
Secondary Immune Response
20%
Vaccination Policy
15%
Vaccine Efficacy
75%
Viral Disease
15%
Viral Pathogenesis
15%
Viral Vector
15%
Virus Vaccine
15%